Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Custirsen with Second-Line Chemotherapy in HRPC
NCT00327340Phase 2Completed
- Sponsor
- Achieve Life Sciences
- Start
- Jul 2006
- Primary completion
- Oct 2010
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of custirsen in prostate cancer (PCa) (2 arms), sponsored by Achieve Life Sciences. Primary endpoint: Safety and Tolerability of Custirsen (OGX-011) in Combination With Either Docetaxel/Prednisone or Mitoxantrone/Prednisone at 8 months. Started Jul 2006; status: completed.
02
Drugs
custirsen
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00327340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00327340.